Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind study of VTX958 in moderately to severely active Crohn's disease
MOH_2023-04-19_012550Phase 2Active, not recruiting
- Sponsor
- Ventyx Biosciences
- Start
- Mar 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cenacitinib in Crohn's disease (3 arms), sponsored by Ventyx Biosciences. Started Mar 2023; status: active, not recruiting.
02
Drugs
cenacitinib
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on MOH_2023-04-19_012550.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-04-19_012550.